AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by research analysts at Berenberg Bank in a research report issued to clients and investors on Monday. They currently have a GBX 5,500 ($71.03) price objective on the biopharmaceutical company’s stock. Berenberg Bank’s price target would suggest a potential upside of 14.82% from the stock’s previous close.
AZN has been the subject of several other research reports. Liberum Capital restated a “buy” rating and issued a GBX 4,800 ($61.99) target price on shares of AstraZeneca plc in a report on Tuesday, September 5th. Morgan Stanley restated an “overweight” rating and issued a GBX 5,600 ($72.32) target price on shares of AstraZeneca plc in a report on Friday, June 23rd. UBS AG set a GBX 4,550 ($58.76) target price on shares of AstraZeneca plc and gave the company a “neutral” rating in a report on Thursday, August 31st. Deutsche Bank AG restated a “buy” rating on shares of AstraZeneca plc in a report on Monday, May 22nd. Finally, Barclays PLC restated an “overweight” rating and issued a GBX 6,000 ($77.49) target price on shares of AstraZeneca plc in a report on Monday, June 5th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company’s stock. AstraZeneca plc presently has a consensus rating of “Hold” and an average price target of GBX 4,963.82 ($64.11).
AstraZeneca plc (LON:AZN) opened at 4871.50 on Monday. The firm has a 50 day moving average of GBX 4,593.39 and a 200-day moving average of GBX 4,871.66. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The stock’s market cap is GBX 61.67 billion.
AstraZeneca plc (LON:AZN) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $1.01. AstraZeneca plc had a net margin of 8.83% and a return on equity of 14.36%. On average, analysts expect that AstraZeneca plc will post $3.75 earnings per share for the current year.
In related news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The shares were acquired at an average cost of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.